Royalty Pharma (NASDAQ:RPRX) EVP Marshall Urist Sells 20,000 Shares of Stock

Royalty Pharma PLC (NASDAQ:RPRX) EVP Marshall Urist sold 20,000 shares of the business’s stock in a transaction that occurred on Friday, December 26th. The shares were sold at an average price of $39.32, for a total transaction of $786,400.00. Following the completion of the sale, the executive vice president directly owned 100,000 shares in the company, valued at approximately $3,932,000. This trade represents a 16.67% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Marshall Urist also recently made the following trade(s):

• On Friday, December 19th, Marshall Urist sold 20,000 shares of Royalty Pharma stock. The stock was sold at an average price of $38.38, for a total transaction of $767,600.00.
• On Tuesday, December 16th, Marshall Urist sold 20,000 shares of Royalty Pharma stock. The shares were sold at an average price of $38.32, for a total transaction of $766,400.00.
• On Friday, December 5th, Marshall Urist sold 23,334 shares of Royalty Pharma stock. The stock was sold at an average price of $39.15, for a total value of $913,526.10.
• On Friday, December 5th, Marshall Urist sold 18,242 shares of Royalty Pharma stock. The stock was sold at an average price of $39.15, for a total value of $714,174.30.
• On Monday, December 1st, Marshall Urist sold 23,333 shares of Royalty Pharma stock. The shares were sold at an average price of $39.93, for a total value of $931,686.69.
• On Monday, December 1st, Marshall Urist sold 18,242 shares of Royalty Pharma stock. The shares were sold at an average price of $39.90, for a total value of $727,855.80.

Royalty Pharma Stock Performance

Shares of RPRX opened at $39.08 on Tuesday. Royalty Pharma PLC has a 52-week low of $25.18 and a 52-week high of $41.24. The stock’s 50-day simple moving average is $38.71 and its 200 day simple moving average is $37.01. The company has a debt-to-equity ratio of 0.89, a quick ratio of 3.48 and a current ratio of 3.48. The stock has a market capitalization of $22.56 billion, a price-to-earnings ratio of 29.61, a price-to-earnings-growth ratio of 2.06 and a beta of 0.46.

Royalty Pharma (NASDAQ:RPRX) last announced its quarterly earnings results on Wednesday, November 5th. The biopharmaceutical company reported $1.17 earnings per share for the quarter, beating the consensus estimate of $1.11 by $0.06. Royalty Pharma had a return on equity of 26.36% and a net margin of 32.51%.The firm had revenue of $609.29 million for the quarter, compared to analysts’ expectations of $765.01 million. Research analysts forecast that Royalty Pharma PLC will post 4.49 EPS for the current fiscal year.

Royalty Pharma Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th were issued a $0.22 dividend. This represents a $0.88 annualized dividend and a yield of 2.3%. The ex-dividend date of this dividend was Friday, November 14th. Royalty Pharma’s dividend payout ratio (DPR) is presently 66.67%.

Institutional Investors Weigh In On Royalty Pharma

Several hedge funds have recently added to or reduced their stakes in the company. Smartleaf Asset Management LLC increased its position in shares of Royalty Pharma by 868.1% during the 3rd quarter. Smartleaf Asset Management LLC now owns 881 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 790 shares during the last quarter. USA Financial Formulas bought a new position in Royalty Pharma during the second quarter valued at approximately $32,000. Financial Consulate Inc. purchased a new position in shares of Royalty Pharma during the third quarter worth approximately $35,000. Larson Financial Group LLC raised its stake in shares of Royalty Pharma by 31.9% during the third quarter. Larson Financial Group LLC now owns 1,264 shares of the biopharmaceutical company’s stock worth $45,000 after acquiring an additional 306 shares in the last quarter. Finally, WPG Advisers LLC bought a new stake in shares of Royalty Pharma in the 1st quarter worth approximately $39,000. Institutional investors own 54.35% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently weighed in on RPRX. Weiss Ratings cut shares of Royalty Pharma from a “buy (b-)” rating to a “hold (c+)” rating in a report on Saturday, October 25th. Wall Street Zen lowered Royalty Pharma from a “strong-buy” rating to a “buy” rating in a research note on Friday, November 28th. Leerink Partners set a $45.00 price target on Royalty Pharma in a report on Thursday, December 11th. The Goldman Sachs Group assumed coverage on Royalty Pharma in a research report on Tuesday, September 30th. They set a “buy” rating and a $42.00 price target for the company. Finally, Cowen reissued a “buy” rating on shares of Royalty Pharma in a report on Thursday, December 11th. Five analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $45.60.

Royalty Pharma Company Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.